Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
KURA Stock Chart & Stats
$8.46
-$0.35(-4.35%)
At close: 4:00 PM EST
$8.46
-$0.35(-4.35%)
Day’s Range― - ―
52-Week Range$5.41 - $12.49
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.29M
Market Cap
$738.78M
Enterprise Value$660.35M
Total Cash (Recent Filing)$549.66M
Total Debt (Recent Filing)$19.47M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 03, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding87,017,520
10 Day Avg. Volume1,324,804
30 Day Avg. Volume1,288,928
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)1.81
Price to Sales (P/S)13.93
P/FCF Ratio5.61
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue6.35
Enterprise Value/Gross Profit6.55
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$30.14Price Target Upside256.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityCombination data showing high response rates, deepening measurable residual disease clearance, and low rates of differentiation syndrome and QTc issues suggest a competitive clinical profile that could drive broad adoption with standard regimens.
Commercial LaunchKomzifti's approval and U.S. commercial availability with meaningful initial sales and early physician uptake supports expectations of sequential revenue growth and establishes the drug as a commercial player.
Guideline Recognition And Market AccessCategory 2A inclusion by clinical guidelines and potential publication of combination trial results could increase physician prescribing and facilitate adoption in community oncology settings.
Bears Say
Investor Skepticism And Early Clinical MaturityElevated short interest coupled with relatively early follow-up on measurable residual disease kinetics and depth of remission versus competitors could increase stock volatility and delay investor confidence until longer-term data mature.
Pricing And Payer PressureHigher-than-expected wholesale acquisition cost for Komzifti may constrain payer coverage and limit commercial penetration in cost-sensitive treatment settings.
Share Dilution RiskAnalyst caution that increases in share count could dilute earnings per share and negatively affect reported quarterly earnings metrics, pressuring the stock.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.41 and its highest was $12.49 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $738.78M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Mar 03, 2026 which is in 8 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 04, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.12.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.66.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 87,017,520 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 1.945%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.14 (256.26% Upside)
$30.14 (256.26% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 472.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $536.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.80%
12-Months-Change
Fundamentals
Return on Equity
-65.10%
Trailing 12-Months
Asset Growth
35.62%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
KURA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong focus on advancing clinical development, particularly for ziftomenib, with significant progress in trials and preparations for a potential FDA approval. Despite financial challenges, the company's strategic partnerships and clinical advancements position it well for future growth. The sentiment is positive, driven by strong clinical and commercial progress.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$30.14
▲(256.26% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Ownership Overview
2.51% Insiders
10.78% Mutual Funds
14.29% Other Institutional Investors
55.61% Public Companies and
Individual Investors